The National Medical Products Administration officially accepted the listing application of Sanofi's innovative diabetes drug iGlarLixi

Shanghai, September 28, 2021/PRNewswire/ - Sanofi China announced that the National Medical Products Administration (NMPA) has formally accepted the company's fixed-proportion combination of basal insulin and GLP-1RA *SOLIQUA® (iGlarLixi) New drug listing application

iGlarLixi is an injectable hypoglycemic drug, which is composed of insulin glargine 100U/mL and risnatide in a fixed ratio

Experts in the diabetes field are confident that this innovative drug will bring benefits to Chinese diabetic patients

Professor Guo Xiaohui, the main investigator of the LixiLan-L CN Phase III clinical trial in China, from the Department of Endocrinology, Peking University First Hospital, said: “China has approximately 129.

Dr.

The results of the global phase III clinical study of iGlarLixi show that in patients who have received oral hypoglycemic drugs, basal insulin or GLP-1 receptor agonists (daily or weekly preparations) but still have poor blood glucose levels, it may be compared with basal insulin or Compared with GLP-1 receptor agonists alone, iGlarLixi has a better effect on reducing the level of glycosylated hemoglobin (HbA1c), and the proportion of patients reaching the standard is higher (HbA1c <7%)

The results of the study also showed that compared with basal insulin, iGlarLixi does not increase the risk of hypoglycemia and weight gain; compared with GLP-1 receptor agonists, iGlarLixi causes fewer gastrointestinal reactions due to the stepwise titration of doses

In June of this year, Sanofi announced the results of SoliMix, the first head-to-head study comparing iGlarLixi and premixed insulin at the annual meeting of the American Diabetes Association (ADA)

* Soliqua® (iGlarLixi) has not yet been approved in China

[1] Yongze Li, Di Teng, Xiaoguang Shi, et al.

[2] Aroda, Vanita R.

[3] Rosenstock, Julio, et al.

[4] Blonde L, et al.

[5] Rosenstock, Julio et al.

About Sanofi China

Sanofi is a leading global biopharmaceutical company focusing on human health

For more information, please visitor follow the "Sanofi China" WeChat official account and "Sanofi" LinkedIn account

About Sanofi

Sanofi is committed to helping people cope with health challenges

Sanofi has more than 100,000 employees in more than 100 countries, committed to transforming scientific innovations into medical and health solutions

Sanofi, Empowering Life Sanofi, Empowering Life

Sanofi's forward-looking statements 

This press release contains forward-looking statements
.
Forward-looking statements are not statements of historical facts
.
These statements include forecasts and estimates and basic assumptions, statements about the company's future plans, goals, and intentions, prospects for future financial conditions, events, operations, services, product development and potential, and statements about future performance
.
Generally, words such as "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions can be used as the basis for determining forward-looking statements
.
Although Sanofi’s management believes that the expectations reflected in this forward-looking statement are reasonable, investors should still note that these forward-looking information and statements are subject to many risks and uncertainties, many of which are difficult to predict and are generally not Sanofi controls, which may cause actual results and developments to differ materially from those expressed, implied or predicted in forward-looking information and statements
.
These risks and uncertainties mainly include the inherent uncertainties in research and development, future clinical data and analysis, including the data and analysis performed after the product is marketed, and the decisions of regulatory authorities, such as the US Food and Drug Administration The decision of the Agency or the European Medicines Agency on whether and when to approve the marketing of any drugs, medical devices or biological products that may be filed for candidate products, as well as the product labeling and other products that may affect the availability and commercial potential of such candidate products Decisions on matters such as the possibility of commercial success of approved candidate products, the approval of future alternative therapies and their commercial success, the group will benefit from external growth opportunities and completion of related transactions and/or obtaining regulatory approvals Capacity, risks associated with intellectual property rights and any related pending or future litigation and the final outcome of such litigation, turbulent economic and market conditions, the impact of global destruction including global epidemics, exchange rate trends and general Interest rates, cost control policies and the resulting results, the average number of issued shares, and Sanofi’s publicly submitted reports to the US Securities and Exchange Commission (SEC) and the French Financial Market Authority (AMF) have discussed or The clear part, including the "risk factors" and "warning of forward-looking statements" in Sanofi's annual report (as of December 31, 2020) listed in Table 20-F
.
Unless applicable legal requirements exist, Sanofi assumes no obligation to update or revise any forward-looking information and statements
.

Source: Sanofi China